Health Economics Flashcards

1
Q

Basics of health economics is?

A

That we have to utilize opportunity cost and make up our mind of a new therapy has the best value according to other opportunity costs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Considerations in health economics

A
  • Lives saved
  • Quality of life (very subjective and difficult to calculate)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is horizontal and vertical equity?

A

Horizontal equity requires that individuals with similar characteristics (i.e. need) of medical relevance to be treated similarly

Vertical equity permits differential treatment of individuals with different characteristics (needs) (think ventilators during covid and a 20 year old vs. 80 year old. It’s more expensive to lose the 20 year old and they get more added value (life years), and thus they get the ventilator)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe horizontal and vertical equity in COVID

A

A lof of vertical equity (younger people getting respirators, vaccines getting to risk groups first, vaccines going to western countries before 3rd world countries, lockdown affecting young people more than old people).

Horizontal equity in testing most of the time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cost effectiveness analysis in health economics include what two main concepts?

A

QALY (Quality Adjusted Life Years) and ICER (Incremental Cost Effectiveness Ratio)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is a QALY

A

Quality Adjusted Life Years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is ICER?

A

Incremental Cost Effectiveness Ratio – the “Marginal Cost” of an extra life year.

Start with the cheapest option an see how many more QALY’s you can create and at what cost. A = 4K for 6 QALYS, B = 8K for 7 QALY = 1 more QALY for 4K = ICER = 4K.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the thing about ICER and domination?

A

Dominated alternatives are left out

If you have a product that is more expensive and offers less QALYs than several other products, it’s left out.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is HRQL? And how is it measured?

A

HRQL - Health-Related Quality of Life
HRQL measured through questionaires

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How are QALYs calculated?

A

QALYs are generated by the summation across all health states of the length of time in a particular health state multiplied by a weight representing the HRQoL attached to that health state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are incremental QALYs?

A

The incremental added QALYs between different products when comparing them. Often together with ICER.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you make prices in pharma?

A

Value-based. The more QALY you create the higher the value, the higher the price.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the price of a QALY in UK?

A

20.000 pounds – very public number.

NICE
NHS - National Healthcare System

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Are all QALYs treated equally?

A

No, end of life QALYs have higher prices as they are more valuable than earlier QALYs. Think; You have one year to live, is worth more than a year in “You have 20 years to live”.

Treatments that add QALYs restoring health and sustained over a very long period, burden of illsness and societal impact also are more expensive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Where is the limit for a QALY based on Pauldon?

A

NICE has a limit of 20K pounds, Pauldan says that if it is above 13.000 pounds, QALY are lost for other patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Can wider societal impacts be included in medicinrådets decisions?

A
  • No! It opens the door for giving or excluding medicine to social groups. I.e. treating drug addicts differently than non-drug addicts.
17
Q

What is price anchoring?

A

That the starting price defines an anchor an makes you illogical. “Price is 200, now only 50DKK”  Wow that’s cheap.

18
Q

Is there a correlation between price and incremental survival benefits?

A

YES! Significant positive correlation between prices and incremental survival benefits
(Hovard et al 2015)

19
Q

Are drugs getting more expensive?

A

Yes!

20
Q

What is reference pricing and the issue with it?

A

Setting the price based on the references in the market (similar products), but higher if the effect is better. This establishes a new reference point, increasing prices further. Cannot be explained by competitive pricing nor cost.